Treatment of HIV infection with cytoreductive agents. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Treatment of HIV infection with cytoreductive agents.

AIDS Res Hum Retroviruses. 1998 Oct 10;14(15):1305-13. Unique Identifier : AIDSLINE MED/99002720
Smith C; Lilly S; Miralles GD; Department of Medicine, Duke University Medical Center, Durham,; North Carolina 27710, USA.

Abstract: Advances in antiretroviral therapy have resulted in significant improvement in virological markers and clinical end points. However, studies have demonstrated that HIV can be recovered from patients in whom HIV RNA has been undetectable for prolonged periods of time, suggesting that the elimination half-life of latently infected cells may be longer than previously speculated. When used in the appropriate setting, cytoreductive agents may help expedite the elimination of the long-lived viral reservoir, and result in shorter administration of antiviral agents. In this article we discuss the potential use of cytoreductive agents as adjunctive therapy to antiretrovirals. In addition, we review those agents most likely to impact the viral reservoir and describe ongoing clinical trials designed to define the effect of cytoreductive therapy on those reservoirs. If a positive effect is demonstrated, these agents could ultimately be a powerful addition to the potent drugs currently being used to block HIV replication.
Keywords: JOURNAL ARTICLE Adjuvants, Immunologic/THERAPEUTIC USE Anti-HIV Agents/*THERAPEUTIC USE Clinical Trials Hematopoietic Stem Cell Transplantation Human HIV Infections/*DRUG THERAPY/RADIOTHERAPY Immunosuppressive Agents/THERAPEUTIC USE Myeloablative Agonists/THERAPEUTIC USE Support, Non-U.S. Gov'tKWDjournalarticleadjuvants,immunologic/therapeuticuseanti-hivagents/KWDtherapeuticuseclinicaltrialshematopoieticstemcelltransplantationhumanhivinfections/KWDdrugtherapy/radiotherapyimmunosuppressiveagents/therapeuticusemyeloablativeagonists/therapeuticusesupport,non-uKWDsKWDgov't
990228
A9920900

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .